Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. - Wikidata - thesis-toulmin - TriplyDB

Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.

Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.

http://www.wikidata.org/entity/Q34981419

about

Does accumulation of advanced glycation end products contribute to the aging phenotype?Investigating Prevalence and Pattern of Long-term Cardiovascular Disorders in Sulphur Mustard-exposed Victims and Determining Proper Biomarkers for Early Defining, Monitoring and Analysis of Patients' Feedback on Therapy.Serum carboxymethyl-lysine, disability, and frailty in older persons: the Cardiovascular Health Study.Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study.Relationship of an advanced glycation end product, plasma carboxymethyl-lysine, with slow walking speed in older adults: the InCHIANTI study.Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial.Advanced glycation/glycoxidation endproduct carboxymethyl-lysine and incidence of coronary heart disease and stroke in older adults Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study.Endogenous secretory receptor for advanced glycation end products is associated with low serum interleukin-1 receptor antagonist and elevated IL-6 in older community-dwelling adults.Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults.Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults Serum level of endogenous secretory receptor for advanced glycation end products and other factors in type 2 diabetic patients with mild cognitive impairment Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study Dietary advanced glycation end products and aging.Relationship of Soluble RAGE with Insulin Resistance and Beta Cell Function during Development of Type 2 Diabetes Mellitus.Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study.Dietary intake associated with serum versus urinary carboxymethyl-lysine, a major advanced glycation end product, in adults: the Energetics Study sRAGE and risk of diabetes, cardiovascular disease, and death Carboxymethyl lysine, an advanced glycation end product, and incident diabetes: a case-cohort analysis of the ARIC Study.Curcumin and Boswellia serrata Modulate the Glyco-Oxidative Status and Lipo-Oxidation in Master Athletes.EDTA Chelation Therapy to Reduce Cardiovascular Events in Persons with Diabetes.Circulating soluble receptor for advanced glycation end product: Cross-sectional associations with cardiac markers and subclinical vascular disease in older men with and without diabetes.Glycation and cardiovascular disease in diabetes: A perspective on the concept of metabolic memory.Effect of Nɛ-carboxymethyllysine on oxidative stress and the glutathione system in beta cells.Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121.Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes.Curcumin against advanced glycation end products (AGEs) and AGEs-induced detrimental agents.

P2860

Q24632710-931CD21F-875C-4DFF-8E0F-CE1E15F75D70 Q30245541-9A79F3F8-7720-41BC-8ADD-48B54122D0B0 Q30578167-2F97CC01-9365-4E0D-97EC-5953A0E58104 Q33592848-183D8415-D092-449A-9E3A-12BE7D97C8B2 Q33603990-E3FDDED9-D8D8-4F47-AF28-0F9795B53DDB Q33752140-4DD917F3-67DD-4DF2-9EC7-F5DDAE40C974 Q34217710-886FFA5A-24C8-48A5-9B27-A6B8701EB911 Q34507243-7EF5EE38-D4B7-4DD5-8556-41A2D3DCF691 Q34660313-CEEF8E16-8482-4C6D-9F0F-2721D4F0EBC1 Q34885399-BA5D86EE-088E-418D-8B04-39E3AD4ABC35 Q35173430-B6781648-6DEA-44F4-9907-672032644590 Q35563671-8D25375F-8F7F-4EFE-9587-E2C2CA8CB4E9 Q35666321-C3C1D034-62B4-4850-B962-E65F20880C94 Q35670859-835F9F26-F35A-4478-8C9F-6F2611799A94 Q35674689-F36CB5A3-E492-48EA-B2E4-86E8E038A81A Q35907814-944F3453-B6A4-494D-BC4A-A4EDD8440A9D Q36047141-A765915C-7791-4392-BE00-3FECF6DDEC7C Q36263332-61DD2FC1-6958-466A-B18E-00570A29A176 Q36364486-917CF75E-30E1-455A-9A22-41017C890F33 Q36867450-A2E32530-B522-484A-8DDC-295CDC065FDF Q37056383-840BFADD-3753-4761-8617-BC41EBE8D4C1 Q37463412-C5DA7A06-7845-4736-A11D-5944B064CFBB Q38585738-C7DF788B-7D76-4FE4-9502-AE2FF293D6D1 Q38651423-B8499E58-3546-4E66-858E-EB850D0FE52A Q38936100-A0E17A3B-17DF-432D-82FE-34C812B97F2C Q41681406-53A234B3-21B9-4171-8565-BD8AD1D9FA4C Q42970461-345A94DA-B777-43AA-AB09-E3EB3737970B Q47687003-6217CF82-3E92-4C86-AC3C-DBA830A07F7F Q49554778-44570E0E-F7AA-4BEA-8C89-0FB04740999F

P2860

Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women.

http://www.wikidata.org/entity/Q34981419

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Advanced glycation end product ...... lder community-dwelling women.

@ast

Advanced glycation end product ...... lder community-dwelling women.

@en

Advanced glycation end product ...... lder community-dwelling women.

@nl

type

label

Advanced glycation end product ...... lder community-dwelling women.

@ast

Advanced glycation end product ...... lder community-dwelling women.

@en

Advanced glycation end product ...... lder community-dwelling women.

@nl

prefLabel

Advanced glycation end product ...... lder community-dwelling women.

@ast

Advanced glycation end product ...... lder community-dwelling women.

@en

Advanced glycation end product ...... lder community-dwelling women.

@nl

P1433

Q34981419-924F4B28-69EC-4D85-819A-14E327EB0DB6

P1476

Q34981419-9E5BB3D6-F0C8-4985-AFE9-BA93D9AF4EE2

P2093

Q34981419-1B586999-7342-4E6A-B7F9-ADEFA7580C94

Q34981419-2C8DE96C-024E-464C-AC97-C179D2FD234D

Q34981419-504E2699-4384-408D-89C2-EF9C63C51885

Q34981419-7720F1E7-BD19-4E35-A4C2-E73089BC9D71

Q34981419-C68B81CC-1CF8-4FEE-87DF-80175CF446A7

Q34981419-C9E81354-63CB-4A78-B045-CB19EF521B3E

P2860

Q34981419-03F1B6F6-8D13-4E29-B9EA-CAD8BBBBA197

Q34981419-22AE737E-25C3-4649-97DC-9EC7AA2D6322

Q34981419-22F11A82-3E3A-44B9-9482-5B291E550F45

Q34981419-25D7208B-5A2C-40B7-A33E-36A961E20230

Q34981419-272B0A01-BE70-4D25-B444-246D86B10BC2

Q34981419-2EBD11C8-01A9-404D-8340-1EEFC8CD021A

Q34981419-4462B1BF-AE07-4EA5-85E8-79ADA295B7C4

Q34981419-44E6DBF6-D167-4279-ABCC-8A0203FE1FDE

Q34981419-4D882341-DBF9-4FA7-A3A0-D77B723C43EF

Q34981419-50852075-BC97-47A4-B331-E21D57846ECD

P2888

Q34981419-4983F911-5978-49B5-A160-B345549638E4

P304

Q34981419-6D65D621-A6C6-4C5D-A9E3-B3D13C467B63

P31

Q34981419-9214ED82-803D-44B7-AE76-AAC0D111C48C

P356

Q34981419-69346E2B-69F0-4270-B8F6-3413EB7C3C9B

P433

Q34981419-CF3E9814-D6A3-416B-8D4B-ECBA914E0B08

P478

Q34981419-B54D8BC7-14DA-464F-BA75-E002A226983E

P50

Q34981419-52CFDC7F-38A8-4BFE-B1BC-CC6775C89139

Q34981419-D375274E-473A-4F1D-BFE8-E6B0837F46F8

Q34981419-EF7F212F-3308-4457-89FE-A6230040F257

P577

Q34981419-75730210-E26D-4065-9EE9-77AC22A952A9

P6179

Q34981419-FC415128-C960-4029-8F64-4882B1328A5A

P698

Q34981419-0DDC7AD6-242D-4A8A-A78F-BE85D9595824

P921

Q34981419-EB3D5065-11BB-4E64-A8A2-6F2807B1AA61

P932

Q34981419-48DF707A-05C0-48FF-A037-C3C9B1262894

P356

P1433

Aging Clinical and Experimental Research

P1476

Advanced glycation end product ...... lder community-dwelling women.

@en

P2093

Jack M Guralnik

http://www.w3.org/2001/XMLSchema#string

Jeremy Walston

http://www.w3.org/2001/XMLSchema#string

Justine Beck

http://www.w3.org/2001/XMLSchema#string

Linda P Fried

http://www.w3.org/2001/XMLSchema#string

Mansi Dalal

http://www.w3.org/2001/XMLSchema#string

Ravi Varadhan

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins

Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy

“Mini-mental state”

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus.

Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy

The worldwide obesity epidemic.

Diabetes and advanced glycation endproducts.

P2888

P304

182-190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03325227

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Richard D Semba

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1049457199

http://www.w3.org/2001/XMLSchema#string

P698

19448391

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

2684987

http://www.w3.org/2001/XMLSchema#string